Tyra Biosciences (NASDAQ:TYRA) Given Buy Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of Tyra Biosciences (NASDAQ:TYRA) in a research note released on Monday morning,Benzinga reports. The brokerage currently has a $30.00 target price on the stock.

TYRA has been the topic of a number of other research reports. Wedbush restated an “outperform” rating and issued a $28.00 price target on shares of Tyra Biosciences in a research note on Friday, October 25th. Bank of America raised Tyra Biosciences from a “neutral” rating to a “buy” rating and upped their price objective for the company from $22.00 to $31.00 in a report on Friday, October 18th. Oppenheimer upped their price objective on Tyra Biosciences from $25.00 to $33.00 and gave the company an “outperform” rating in a report on Thursday, September 19th. Finally, UBS Group began coverage on Tyra Biosciences in a report on Tuesday, January 7th. They issued a “buy” rating and a $28.00 price objective on the stock. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $30.50.

Tyra Biosciences Stock Down 0.7 %

NASDAQ:TYRA opened at $15.10 on Monday. Tyra Biosciences has a twelve month low of $12.17 and a twelve month high of $29.60. The business has a 50 day moving average price of $15.45 and a two-hundred day moving average price of $19.22. The company has a market cap of $764.11 million, a P/E ratio of -9.38 and a beta of 1.04.

Tyra Biosciences (NASDAQ:TYRA) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.01). As a group, analysts anticipate that Tyra Biosciences will post -1.57 earnings per share for the current fiscal year.

Insider Transactions at Tyra Biosciences

In related news, Director Nina S. Kjellson sold 11,078 shares of the firm’s stock in a transaction dated Wednesday, October 30th. The stock was sold at an average price of $16.17, for a total value of $179,131.26. Following the sale, the director now directly owns 472,207 shares of the company’s stock, valued at $7,635,587.19. This trade represents a 2.29 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CFO Alan Fuhrman acquired 9,500 shares of Tyra Biosciences stock in a transaction that occurred on Wednesday, October 30th. The stock was acquired at an average cost of $16.00 per share, for a total transaction of $152,000.00. Following the completion of the purchase, the chief financial officer now directly owns 12,849 shares of the company’s stock, valued at $205,584. This represents a 283.67 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders have sold 74,125 shares of company stock valued at $1,583,097. 15.40% of the stock is owned by corporate insiders.

Institutional Trading of Tyra Biosciences

Several large investors have recently bought and sold shares of TYRA. Rhumbline Advisers raised its position in Tyra Biosciences by 12.3% in the second quarter. Rhumbline Advisers now owns 23,572 shares of the company’s stock valued at $377,000 after purchasing an additional 2,574 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in Tyra Biosciences by 2.2% in the third quarter. Charles Schwab Investment Management Inc. now owns 173,737 shares of the company’s stock valued at $4,085,000 after purchasing an additional 3,792 shares during the last quarter. JPMorgan Chase & Co. raised its position in Tyra Biosciences by 1.1% in the third quarter. JPMorgan Chase & Co. now owns 368,647 shares of the company’s stock valued at $8,667,000 after purchasing an additional 3,896 shares during the last quarter. Ally Bridge Group NY LLC raised its position in Tyra Biosciences by 2.0% in the third quarter. Ally Bridge Group NY LLC now owns 270,075 shares of the company’s stock valued at $6,349,000 after purchasing an additional 5,415 shares during the last quarter. Finally, Oppenheimer & Co. Inc. raised its position in Tyra Biosciences by 9.0% in the third quarter. Oppenheimer & Co. Inc. now owns 76,806 shares of the company’s stock valued at $1,806,000 after purchasing an additional 6,318 shares during the last quarter. 84.14% of the stock is owned by institutional investors and hedge funds.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.